Home / About ANZUP

About ANZUP

Founded in 2008, the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) is a not-for-profit cancer research charity dedicated to improving the lives of people affected by urogenital or “below the belt” cancers, including bladder, kidney, testicular, penile, and prostate cancers.

ANZUP brings together more than 2,700 healthcare professionals, researchers, scientists and community representatives from across Australia, New Zealand, and around the world. We identify gaps in evidence and areas of unmet clinical need, working collaboratively to design and deliver practice-changing research and clinical trials. Our research prioritises outcomes that matter most to people affected by urogenital, or “below the belt”, cancers, focusing on both survival and quality of life.

ANZUP receives infrastructure funding from the Australian Government through Cancer Australia. Philanthropic support and fundraising also play an important role in supporting ANZUP’s activities and research.

Every meaningful advance in treatment has been the result of testing a new idea in a clinical trial.

Professor Ian Davis, ANZUP Chair

Our vision: Living life without fear of cancer

Patient-Centred

We prioritise research that delivers outcomes that matter most to patients and their loved ones, including improved quality of life, fewer side effects, and better cancer control and survival.

Independent. Always.

Our research and trials are driven by clinicians and researchers focused on addressing areas of genuine clinical need rather than commercial interests, enabling independent, high-impact discoveries.

Multidisciplinary

We bring together over 2,000 professionals including doctors, nurses, researchers, scientists and community representatives ensuring diverse expertise and perspectives help shape innovative cancer trials.

Seed to Success Model

Our “Below the Belt” Research Grants support bold, innovative ideas with the potential to transform the future of urogenital cancer care, particularly those that may not yet attract government or industry funding. By enabling early-stage research, these grants generate the evidence needed to drive further trials and discoveries that can ultimately change clinical practice and improve patient outcomes.